Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
D 84.03 7.91% 6.16
BHVN closed up 7.91 percent on Friday, March 5, 2021, on 1.62 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical BHVN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Lower Bollinger Band Walk Weakness 7.91%
Multiple of Ten Bearish Other 7.91%
Down 3 Days in a Row Weakness 7.91%
Lower Bollinger Band Touch Weakness 7.91%
MACD Bearish Signal Line Cross Bearish 6.03%
Older End-of-Day Signals for BHVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot about 5 hours ago
20 DMA Resistance about 7 hours ago
Rose Above 20 DMA about 7 hours ago
10 DMA Resistance about 9 hours ago
Rose Above 10 DMA about 9 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biohaven Pharmaceutical Holding Company Ltd. Description

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Degenerative Disease Degenerative Diseases Neurodegenerative Diseases Glutamate Chemical Entity Riluzole

Is BHVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 100.77
52 Week Low 26.56
Average Volume 520,340
200-Day Moving Average 75.82
50-Day Moving Average 84.78
20-Day Moving Average 83.60
10-Day Moving Average 82.36
Average True Range 4.68
ADX 12.97
+DI 19.31
-DI 22.82
Chandelier Exit (Long, 3 ATRs ) 75.73
Chandelier Exit (Short, 3 ATRs ) 89.91
Upper Bollinger Band 89.56
Lower Bollinger Band 77.65
Percent B (%b) 0.54
BandWidth 14.25
MACD Line -0.94
MACD Signal Line -0.81
MACD Histogram -0.1271
Fundamentals Value
Market Cap 5.04 Billion
Num Shares 59.9 Million
EPS -9.14
Price-to-Earnings (P/E) Ratio -9.19
Price-to-Sales 181.98
Price-to-Book 31.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 94.62
Resistance 3 (R3) 93.52 88.88 92.86
Resistance 2 (R2) 88.88 86.18 89.43 92.27
Resistance 1 (R1) 86.46 84.52 87.67 87.56 91.68
Pivot Point 81.82 81.82 82.42 82.37 81.82
Support 1 (S1) 79.39 79.12 80.61 80.50 76.38
Support 2 (S2) 74.76 77.45 75.31 75.79
Support 3 (S3) 72.33 74.76 75.20
Support 4 (S4) 73.44